IOVA in the 13F filings
Iovance Biotherapeutics Inc · CUSIP 462260100
- Quarter end
- 31 Dec 2025
- the date the book describes
- Filed
- 27 Oct 2026
- latest of these filings; the earliest 12 Feb 2026
- Managers listing it
- 24
- at least, of 95 tracked, among listed positions
- Comparable managers
- 92
- filed both Q3 2025 and Q4 2025; 1 listed it in both
- Shares listed
- 35,679,775
- combined, among listed positions
- Reported value
- $97m
- combined, at the quarter end
Among the 92 comparable managers: 15 buyers (opened or added shares) and 5 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was +14,065,578.
Managers listing IOVA in Q4 2025
24 of 24 holders
Largest increases and reductions, by shares
Increases
- D. E. Shaw & Co.existing position · 3,829,795 shares now+3,753,586
- Millennium Management LLCexisting position · 6,585,532 shares now+2,172,081
- Jane Street Group LLCexisting position · 3,583,810 shares now+2,170,148
- Two Sigma Advisers LPexisting position · 3,015,000 shares now+1,956,000
- Two Sigma Investments LPexisting position · 4,397,989 shares now+1,657,135
Reductions
- T. Rowe Price Associates Incexisting position · 1,191,828 shares now-866,190
- Citadel Advisors LLCexisting position · 3,143,091 shares now-677,273
- Balyasny Asset Management LLCexisting position · 68,038 shares now-22,586
- Squarepoint Ops LLCexisting position · 25,001 shares now-18,757
- Fidelity (FMR LLC)existing position · 31,073 shares now-12,508
New positions and exits
New (1)
Exited (0)
No exit shown by a manager’s own filing.
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q3 2017 | 1 | $6.6m | n.a. | n.a. |
| Q4 2017 | 1 | $15m | n.a. | n.a. |
| Q1 2018 | 4 | $72m | n.a. | n.a. |
| Q2 2018 | 3 | $59m | n.a. | n.a. |
| Q3 2018 | 3 | $59m | n.a. | n.a. |
| Q4 2018 | 6 | $73m | n.a. | n.a. |
| Q1 2019 | 5 | $70m | n.a. | n.a. |
| Q2 2019 | 5 | $198m | n.a. | n.a. |
| Q3 2019 | 6 | $166m | n.a. | n.a. |
| Q4 2019 | 7 | $333m | n.a. | n.a. |
| Q1 2020 | 9 | $610m | n.a. | n.a. |
| Q2 2020 | 8 | $624m | n.a. | n.a. |
| Q3 2020 | 9 | $822m | n.a. | n.a. |
| Q4 2020 | 9 | $1.8bn | n.a. | n.a. |
| Q1 2021 | 8 | $1.2bn | n.a. | n.a. |
| Q2 2021 | 6 | $917m | n.a. | n.a. |
| Q3 2021 | 7 | $753m | n.a. | n.a. |
| Q4 2021 | 8 | $517m | n.a. | n.a. |
| Q1 2022 | 8 | $423m | n.a. | n.a. |
| Q2 2022 | 7 | $121m | n.a. | n.a. |
| Q3 2022 | 8 | $100m | n.a. | n.a. |
| Q4 2022 | 6 | $43m | n.a. | n.a. |
| Q1 2023 | 6 | $102m | n.a. | n.a. |
| Q2 2023 | 4 | $102m | n.a. | n.a. |
| Q3 2023 | 4 | $35m | n.a. | n.a. |
| Q4 2023 | 7 | $105m | 3 | 4 |
| Q1 2024 | 5 | $154m | 2 | 3 |
| Q2 2024 | 4 | $98m | 1 | 2 |
| Q3 2024 | 4 | $93m | 1 | 2 |
| Q4 2024 | 3 | $52m | 1 | 1 |
| Q1 2025 | 3 | $19m | 1 | 1 |
| Q2 2025 | 1 | $45k | 0 | 1 |
| Q3 2025 | 1 | $56k | 0 | 0 |
| Q4 2025 | 1 | $71k | 15 | 5 |
| Q1 2026 | 2 | $1.3m | 20 | 6 |
| Q2 2026 | 1 | $79m | 15 | 13 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
IOVA and GILD →IOVA and AMGN →IOVA and ARGX →Choose a stock to compare with IOVA →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own IOVA, latest filings →Back to the 13F Explorer →